Business

Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation

July 22nd 2020

By Tony Hagen

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 22nd 2020

A panel of experts discusses the ways in which payers restrict prescribing choices for physicians and what that means for the future of biosimilar utilization.

Rathore Discusses Study on Biosimilar Application Failures

July 22nd 2020

The Center for Biosimilars® interviewed Anurag S. Rathore, PhD, whose team of investigators evaluated why applications for biosimilar approvals do not succeed. Large companies as well as small find the approval process challenging, but there is a learning curve that may be followed by more consistent approvals, he explains.

Webinar: Choice Is Vital to Biosimilar Savings Picture

July 21st 2020

By Tony Hagen

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars.

New Battleground Shaping Up Over Insulin Deliverables

July 20th 2020

By Tony Hagen

With insulin originator product patents expiring, drug companies are seeking to extend exclusivities via patents on injectors and other delivery products.

World's First Halal Biosimilar to Be Produced in Malaysia

July 20th 2020

By Tony Hagen

As part of a project to build the first biosimilar factory in Malaysia, one of the initial products would be halal certified.

Byoungseo Choi on Celltrion's Biosimilar Goals For 2030

July 19th 2020

We sat down with Byoungseo Choi, the head of marketing for Celltrion Healthcare, to discuss exactly how this plan is going to work, the company’s current biosimilar pipeline, and its expectations for how their products will perform.

Why Biosimilar Approval Applications Break Down

July 17th 2020

By Tony Hagen

Investigators found that process complexities have created numerous difficulties for biosimilar developers in regulatory filings, but they anticipate that the success rate will improve with experience and improved guidance.

Part 2: Celltrion Marketing Head Discusses Company's Future

July 16th 2020

Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses Celltrion’s biosimilar pipeline, the competitive landscape for its products, and its plans to build a biosimilar production center in Wuhan, China.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 16th 2020

By Tony Hagen

An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.